Free shipping on all orders over $ 500

 About 7 results found for searched term "ERK5-IN-6" (0.132 seconds)

Cat.No.  Name Target
M49711 ERK5-IN-6 ERK
ERK5-IN-6 is an ERK5 kinase inhibitor with anticancer activity.
M6160 Bohemine CDK
Bohemine is A selective CDK inhibitor with IC50 of 4.6 μM, 83 μM and 2.7 μM against Cdk2/ Cyclin E, Cdk2/ Cyclin A and Cdk9/cyclin T1, respectively. Bohemine also inhibited ERK2, IC50 was 52 μM, and inhibited CDK1, CDK4 and CDK6. Bohemine is also a purine analogue and has a wide range of anticancer activities.
M20811 XMD8-85 (ERK5-IN-1) ERK
XMD8-85 (ERK5-IN-1) is a selective and potent inhibitor of ERK5 and LRRK2 with IC50s of 0.162 μM and 0.339 μM, respectively.
M30350 E6201 MEK
ER-806201
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC50 value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC50 value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC50 value of 19 nM. Anti-tumor and anti-psoriasis efficacy.
M30754 PT-262  ROCK
PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity.
M45287 CK2/ERK8-IN-1 Casein Kinase
CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) (Ki 0.25 µM) and ERK8 (MAPK15, ERK7), both with IC50s of 0.50 µM. In addition, CK2/ERK8-IN-1 binds to PIM1, HIPK2, and DYRK1A with Ki values of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. 15.25 µM and 11.9 µM, respectively, and also has pro-apoptotic activity.
M49708 ERK5-IN-3 ERK
ERK5-IN-3 is a potent and selective ERK5 (extracellular signal-related kinase 5) inhibitor, with an IC50 of 6 nM.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.